Corvus Pharmaceuticals (CRVS) Total Current Liabilities (2015 - 2026)

Corvus Pharmaceuticals' Total Current Liabilities history runs 12 years deep, the most recent figure standing at $12.1 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 30.51% year-over-year to $12.1 million; the TTM figure through Mar 2026 stood at $12.1 million (up 30.51% YoY), while the FY2025 annual figure was $9.4 million, down 73.5% from the prior year.
• Total Current Liabilities was $12.1 million for Q1 2026 at Corvus Pharmaceuticals, up from $9.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $46.4 million in Q3 2024 to a low of $6.7 million in Q1 2024.
• Historically, Total Current Liabilities has averaged $13.2 million across 5 years, with a median of $9.3 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities surged 535.79% in 2024, then slumped 82.6% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $10.8 million in 2022, then tumbled by 36.11% to $6.9 million in 2023, then soared by 415.39% to $35.4 million in 2024, then slumped by 73.5% to $9.4 million in 2025, then climbed by 29.1% to $12.1 million in 2026.
• The last three Total Current Liabilities figures came in at $12.1 million (Q1 2026), $9.4 million (Q4 2025), and $8.1 million (Q3 2025), per Business Quant data.